rs137852761
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_005591.4(MRE11):c.1714C>T(p.Arg572Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000936 in 1,613,564 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000066 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000096 ( 0 hom. )
Consequence
MRE11
NM_005591.4 stop_gained
NM_005591.4 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 6.45
Genes affected
MRE11 (HGNC:7230): (MRE11 homolog, double strand break repair nuclease) This gene encodes a nuclear protein involved in homologous recombination, telomere length maintenance, and DNA double-strand break repair. By itself, the protein has 3' to 5' exonuclease activity and endonuclease activity. The protein forms a complex with the RAD50 homolog; this complex is required for nonhomologous joining of DNA ends and possesses increased single-stranded DNA endonuclease and 3' to 5' exonuclease activities. In conjunction with a DNA ligase, this protein promotes the joining of noncomplementary ends in vitro using short homologies near the ends of the DNA fragments. This gene has a pseudogene on chromosome 3. Alternative splicing of this gene results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 11-94447288-G-A is Pathogenic according to our data. Variant chr11-94447288-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 8784.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MRE11 | NM_005591.4 | c.1714C>T | p.Arg572Ter | stop_gained | 15/20 | ENST00000323929.8 | NP_005582.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MRE11 | ENST00000323929.8 | c.1714C>T | p.Arg572Ter | stop_gained | 15/20 | 1 | NM_005591.4 | ENSP00000325863 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000659 AC: 10AN: 151776Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
10
AN:
151776
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000597 AC: 15AN: 251278Hom.: 0 AF XY: 0.0000663 AC XY: 9AN XY: 135796
GnomAD3 exomes
AF:
AC:
15
AN:
251278
Hom.:
AF XY:
AC XY:
9
AN XY:
135796
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000965 AC: 141AN: 1461788Hom.: 0 Cov.: 31 AF XY: 0.000100 AC XY: 73AN XY: 727196
GnomAD4 exome
AF:
AC:
141
AN:
1461788
Hom.:
Cov.:
31
AF XY:
AC XY:
73
AN XY:
727196
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000659 AC: 10AN: 151776Hom.: 0 Cov.: 31 AF XY: 0.0000540 AC XY: 4AN XY: 74084
GnomAD4 genome
AF:
AC:
10
AN:
151776
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
74084
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
9
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Ataxia-telangiectasia-like disorder 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 21, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 15, 2001 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 22, 2018 | The MRE11A c.1714C>T (p.Arg572Ter) variant is a stop-gained variant predicted to cause a premature truncation of the protein. The p.Arg572Ter variant has been reported in at least two studies in which it is found in a compound heterozygous state in two pairs of siblings from two families with ataxia-telangiectasia-like disorder (Pitts et al. 2001; Delia et al. 2004; Federighi et al. 2017). Control data are unavailable for this variant, which is reported at a frequency of 0.00013 in the European (non-Finnish) population of the Exome Aggregation Consortium. The p.Arg572Ter variant protein could not be detected in proband cells due to destabilisation of the variant by nonsense-mediated mRNA decay. In addition, functional assays in patient lymphoblastoid cell lines demonstrated that the p.Arg572Ter variant protein resulted in a defective MRN complex and exhibited enhanced radio sensitivity in colony survival assays (Pitts et al. 2001; Delia et al. 2004). Based on the evidence, the p.Arg572Ter variant is classified as likely pathogenic for ataxia-telangiectasia-like disorder. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Ataxia-telangiectasia-like disorder Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 11, 2023 | Variant summary: MRE11A c.1714C>T (p.Arg572X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 6e-05 in 251278 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in MRE11A causing Ataxia Telangiectasia-Like Disorder (6e-05 vs 0.0013), allowing no conclusion about variant significance. c.1714C>T has been reported in the literature in individuals affected with Ataxia Telangiectasia-like Disorder (Delia_2004, Pitts_2001), along with individuals affected with pancreatic cancer (Hu_2018) and breast cancer (Lolas Hamameh_2017). These data indicate that the variant is likely to be associated with disease. In addition, functional studies utilizing samples from compound heterozygote patients found the nonsense change to cause NMD leading to lack of MRE11A protein expression and causing an increased radiosensitivity (Delia_2004). The following publications have been ascertained in the context of this evaluation (PMID: 28152038, 29922827, 28486781, 15269180, 11371508, 10612394). Four submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 29, 2023 | This sequence change creates a premature translational stop signal (p.Arg572*) in the MRE11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MRE11 are known to be pathogenic (PMID: 23080121, 23912341). This variant is also known as p.R571X. This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia-like disorder (PMID: 11371508, 15269180). This variant is present in population databases (rs137852761, gnomAD 0.01%). ClinVar contains an entry for this variant (Variation ID: 8784). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2021 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 28, 2021 | The p.R572* pathogenic mutation (also known as c.1714C>T), located in coding exon 14 of the MRE11A gene, results from a C to T substitution at nucleotide position 1714. This changes the amino acid from an arginine to a stop codon within coding exon 14. This mutation was reported in two siblings with ataxia telangiectasia-like disorder (ATLD) and was found to result in nonsense-mediated decay (Pitts SA et al. Hum. Mol. Genet. 2001 May;10:1155-62). In addition, two Italian siblings with ATLD were found to be compound heterozygous for this mutation, and their clinical course is well documented (Delia D et al. Hum. Mol. Genet. 2004 Sep;13:2155-63; Palmeri S et al. Cerebellum. 2013 Aug;12:596-9). Of note, this alteration is also designated as R571X in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A;A;A;A
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at